Rachel Bond, MD
Cardiovascular Disease · Gilbert, AZNPI 1811130040
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.9%), speaking fees and grants — rather than concentrated in one kind of arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.7%. Reporting peaked in 2022 at $14,159 and has fallen 85.1% since, to $2,103 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $914.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- E.r. Squibb & Sons, L.L.C.$9K
- Merck$6K
- Biotronik Inc.$5K
- Abiomed$4K
- Edwards Lifesciences$4K
- plus $13K from 13 others
Across 39 payments — averaging $3887.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$149K
- Novartis$3K
What the payments were for
- Consulting fees$23,94246%
- Speaking & faculty fees$19,24537%
- Grants$5,00010%
- Travel & lodging$1,7403%
- Food & beverage$2,1904%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $10,260 |
| E.r. Squibb & Sons, L.L.C. | 9 | $9,471 |
| Merck | 1 | $5,755 |
| Biotronik Inc. | 1 | $5,000 |
| Abiomed | 8 | $4,480 |
| Edwards Lifesciences | 4 | $4,185 |
| Medtronic(2 entities) | 5 | $3,383 |
| Johnson & Johnson | 3 | $3,064 |
| Novartis | 2 | $2,479 |
| Heartflow, Inc. | 2 | $1,643 |
| Amgen | 4 | $1,531 |
| Boston Scientific | 3 | $204 |
| Abbott | 3 | $189 |
| Esperion Therapeutics, Inc. | 1 | $123 |
| Novo Nordisk | 1 | $117 |
| Philips North America LLC | 1 | $115 |
| Boehringer Ingelheim | 3 | $63 |
| AstraZeneca | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$10,260
- Impella$4,277
- XARELTO$3,030
- COREVALVE EVOLUT R$2,000
- FFRct$1,643
- CoreValve Evolut$308
- Mitra Clip system$138
- NEXLETOL$123
- ELCA$115
- Watchman$106
How this compares
$52,116 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 92 | $116,097 |
| EntrestoSacubitril/Valsartan | 61 | $91,458 |
| XareltoRivaroxaban | 26 | $37,434 |
| Repatha SureclickEvolocumab | 23 | $27,873 |
| Repatha SyringeEvolocumab | 22 | $26,005 |
| Praluent PenAlirocumab | 32 | $17,209 |
| Ezetimibe | 118 | $3,252 |
| Metoprolol Succinate | 207 | $2,900 |
| Atorvastatin Calcium | 273 | $2,416 |
| Rosuvastatin Calcium | 194 | $2,246 |
| Losartan Potassium | 80 | $993 |
| Carvedilol | 94 | $944 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 13 | $767 |
| Amlodipine Besylate | 93 | $729 |
| ClopidogrelClopidogrel Bisulfate | 41 | $611 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $10,260 | $116,09792 claims |
| NovartisEntresto | $2,479 | $91,45861 claims |
| Johnson & JohnsonXarelto | $3,064 | $37,43426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Gilbert
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven MottlTucson$340K
- Paul UnderwoodScottsdale$259K
- Omar WaniFlagstaff$244K
- Robert BurkeScottsdale$207K
- Andrew KaplanMesa$204K
- Tabitha MoePhoenix$182K
- Karl KernTucson$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.